MONTPELIER — Vermont’s attorney general says the state will receive $1.1 million as part of a national settlement with pharmaceutical manufacturer GlaxoSmithKline over allegations that the company deceptively marketed a diabetes drug.

The complaint accuses GlaxoSmithKline LLC of engaging in unfair and deceptive practices by misrepresenting Avandia’s cardiovascular risks and safety profile.

Vermont Attorney General William Sorrell said Thursday that GlaxoSmithKline has reached a $90 million settlement with 37 other attorneys general and has agreed to change how it markets and promotes diabetes drugs.